CanaQuest Medical Corp, an award-winning Life Science/Pharmaceutical company (International CBD Excellence Award 2020 recipient) has scientifically developed, through preclinical trials in conjunction with Dr. Steven Laviolette and his 13-member team at Western University, two commercial-ready Master Formulations, Mentanine® and Mentabinol®, for treating multiple mental health ailments.
Mentanine® – CBD isolate/Omega-3 compounds, has 10X the efficacy compared to Pure CBD for treating anxiety, depression, and PTSD. Evidence also demonstrated significant reductions of inflammation, which could be beneficial for pain. Mentanine® requires lower doses of CBD to achieve the same efficacy compared to higher doses, minimizing negative side-effects of high CBD consumption.
Mentabinol® – THC isolate/L-Theanine formula, the only safer alternative medication to any THC product on the market, protecting all THC users from negative psychiatric side-effects. Preclinical trials demonstrated reversal of depression-like and schizophrenia-related symptoms, blockage of memory impairment, hyperactive activity and gene vulnerability.
CanaQuest has identified the Rx regulatory pathways to obtain Pharmaceutical Drug approvals in Canada and the USA for Epilepsy, a rare neurological condition. Preclinical trials highlight advantages over the FDA-approved CBD drug for treating seizures – Lennox-Gastaut and Dravet syndromes.
The Company is leveraging from Dr. Laviolette’s pre-clinical trial results and is in the process of initiating human trials with selected Universities and an Institution.
The Company will be selling both products (non-Rx) in the coming months to patients through ADC BioMedical Corp, its wholly owned subsidiary, which was awarded a Cannabis Medical Sales Import/Export License from Health Canada under the Cannabis Act.